Development of functionalized hydroxyapatite/poly(vinyl alcohol) composites

Abstract Based on the well-known pharmaceutical excipient potential of poly(vinyl alcohol) (PVA) and clinical success of hydroxyapatite (HAp), the objective of this work was to fabricate functionalized composite microgranules. PVA was modified with succinic anhydride to introduce carboxyl groups (–COOH), respectively, by reaction between the –OH groups of PVA and succinic anhydride, for attachment of drug molecules. For the first time, the functionalized composite microgranules containing HAp/PVA in the ratio of 1:1 were prepared through in situ precipitation of HAp in modified PVA aqueous solutions followed by spray drying of obtained suspensions. The microgranules were characterized by Fourier-transform infrared spectroscopy (FT-IR), X-ray diffraction (XRD), field emission scanning electron microscopy (FE-SEM), and differential scanning calorimetry (DSC). The presence of –COOH groups was verified by FT-IR, and the amount of functional groups added to PVA molecules (averaging 15 mol%) was determined by nuclear magnetic resonance spectroscopy (NMR). DSC results showed that modification with –COOH groups slightly decreased the thermal stability of PVA. FT-IR and XRD analysis confirmed that the resulting composites contain mainly nanocrystalline HAp and PVA. Moreover, the images taken by FE-SEM revealed that the microgranules consisted of nanosized HAp crystallites homogenously embedded in the PVA matrix. DSC measurements indicated that decomposition mechanism of the HAp/PVA differs from that of pure PVA and occurs at lower temperatures. However, the presence of HAp had minor influence on the thermal decomposition of the PVA modified with succinic anhydride. The investigation of composite microgranules confirmed interaction and integration between the HAp and PVA.